Antitumor Agents. 272. Structure−Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues
- 11 February 2010
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 53 (5) , 2299-2308
Abstract
Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure−activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19−21 and 24) exerted potent and selective antibreast cancer activity with IC50 values of 0.3, 0.2, 0.1, and 0.1 μg/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than 1 against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against a ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19−21 and 24 as clinical trial candidates is warranted.Keywords
This publication has 25 references indexed in Scilit:
- Antitumor Agents. 266. Design, Synthesis, and Biological Evaluation of Novel 2-(Furan-2-yl)naphthalen-1-ol Derivatives as Potent and Selective Antibreast Cancer AgentsJournal of Medicinal Chemistry, 2009
- The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Nature Clinical Practice Oncology, 2008
- Treatment of metastatic breast cancer: looking towards the futureBreast Cancer Research and Treatment, 2008
- Natural Products as a Robust Source of New Drugs and Drug Leads: Past Successes and Present Day IssuesThe American Journal of Cardiology, 2008
- Plant-derived compounds in clinical trialsDrug Discovery Today, 2008
- New developments in the chemistry and biology of the bioactive constituents of tanshenMedicinal Research Reviews, 2006
- Highly Efficient Alkylation to Ketones and Aldimines with Grignard Reagents Catalyzed by Zinc(II) ChlorideJournal of the American Chemical Society, 2006
- Drug discovery from medicinal plantsLife Sciences, 2005
- Global cancer statistics in the year 2000The Lancet Oncology, 2001
- Transformation of Alkyl N-(Vinyloxy)benzimidates to Alkyloxazoles. Mechanism and ExtensionBulletin of the Chemical Society of Japan, 1994